Terminated PHASE3 INTERVENTIONAL 2-arm NCT00524030

Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

A Double-Blind, Randomized, Multicenter Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions Epilepsies, Partial

Interventions pregabalin 150 mg/day pregabalin 600 mg/day

Updated 10 times since 2017 Last updated: Jan 15, 2021 Started: Sep 30, 2007 Primary completion: Apr 30, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

See termination reason in detailed description.

Other terminated trials from Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

More terminations from Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Other Epilepsies, Partial trials with similar outcome

Browse all Epilepsies, Partial trials

Listed as NCT00524030, this PHASE3 trial focuses on Epilepsies, Partial and remains terminated or withdrawn. Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc., it has been updated 10 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Feb 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Jan 2021 — Feb 2021 [monthly]

Terminated PHASE3
Feb 2019 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Feb 2019 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altoona, United States , Anderson, United States , Atlanta, United States , Beroun, Czechia , Bowling Green, United States , Brno, Czechia , Cedarhurst, United States , Charlotte, United States , Cleveland, United States , Columbus, United States and 51 more locations